News

The Post Office has announced plans to sell off its remaining directly-owned branches, putting around 1,000 employees at risk ...
Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...